BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 38073096)

  • 1. Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms.
    Liu S; He Y; Zhang Y; Zhang Z; Huang K; Deng L; Liao B; Zhong Y; Feng J
    Gut Microbes; 2023 Dec; 15(2):2290331. PubMed ID: 38073096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on gut microbiota in cardiovascular diseases.
    Qian B; Zhang K; Li Y; Sun K
    Front Cell Infect Microbiol; 2022; 12():1059349. PubMed ID: 36439214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiota and Cardiovascular Disease.
    Witkowski M; Weeks TL; Hazen SL
    Circ Res; 2020 Jul; 127(4):553-570. PubMed ID: 32762536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between gut microbiome and cardiovascular disease.
    Peng J; Xiao X; Hu M; Zhang X
    Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and microbiota-derived metabolites in cardiovascular diseases.
    Chen X; Zhang H; Ren S; Ding Y; Remex NS; Bhuiyan MS; Qu J; Tang X
    Chin Med J (Engl); 2023 Oct; 136(19):2269-2284. PubMed ID: 37442759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota in Hypertension and Atherosclerosis: A Review.
    Verhaar BJH; Prodan A; Nieuwdorp M; Muller M
    Nutrients; 2020 Sep; 12(10):. PubMed ID: 33003455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding connections and roles of gut microbiome in cardiovascular diseases.
    Rajendiran E; Ramadass B; Ramprasath V
    Can J Microbiol; 2021 Feb; 67(2):101-111. PubMed ID: 33079568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota.
    Zhao L; Lou H; Peng Y; Chen S; Fan L; Li X
    Diabetes Res Clin Pract; 2020 Nov; 169():108418. PubMed ID: 32891692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota derived metabolites in cardiovascular health and disease.
    Wang Z; Zhao Y
    Protein Cell; 2018 May; 9(5):416-431. PubMed ID: 29725935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.
    Hosseinkhani F; Heinken A; Thiele I; Lindenburg PW; Harms AC; Hankemeier T
    Gut Microbes; 2021; 13(1):1-22. PubMed ID: 33590776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases.
    Huang Y; Zhang H; Fan X; Wang J; Yin Y; Zhang Y; Shi K; Yu F
    J Cardiovasc Transl Res; 2023 Jun; 16(3):581-589. PubMed ID: 36251229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of Gut Microbiota in Cardiovascular Diseases.
    Zhou W; Cheng Y; Zhu P; Nasser MI; Zhang X; Zhao M
    Oxid Med Cell Longev; 2020; 2020():5394096. PubMed ID: 33062141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between polysaccharides and gut microbiota: A metabolomic and microbial review.
    Zhang D; Liu J; Cheng H; Wang H; Tan Y; Feng W; Peng C
    Food Res Int; 2022 Oct; 160():111653. PubMed ID: 36076442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota is a potential goalkeeper of dyslipidemia.
    Lei L; Zhao N; Zhang L; Chen J; Liu X; Piao S
    Front Endocrinol (Lausanne); 2022; 13():950826. PubMed ID: 36176475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases.
    Yntema T; Koonen DPY; Kuipers F
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review).
    Zhu Y; Shui X; Liang Z; Huang Z; Qi Y; He Y; Chen C; Luo H; Lei W
    Int J Mol Med; 2020 Sep; 46(3):936-948. PubMed ID: 32705240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease.
    Al Samarraie A; Pichette M; Rousseau G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
    Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
    mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota-Derived Metabolites and Cardiovascular Disease Risk: A Systematic Review of Prospective Cohort Studies.
    Sanchez-Gimenez R; Ahmed-Khodja W; Molina Y; Peiró OM; Bonet G; Carrasquer A; Fragkiadakis GA; Bulló M; Bardaji A; Papandreou C
    Nutrients; 2022 Jun; 14(13):. PubMed ID: 35807835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?
    Cao H; Zhu Y; Hu G; Zhang Q; Zheng L
    Pharmacol Res; 2023 Jan; 187():106586. PubMed ID: 36460280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.